Its expenses were at Rs 3,334.08 crore, up 37.05 per cent, during the quarter as against Rs 2,432.58 crore of the last fiscal.

With the Japanese government pushing for generic prescription, Lupin is among the companies hunting for acquisitions in a country that is e...

Net sales of the company rose to Rs 3,144.91 crore for quarter under review as compared to Rs 2,982.97 crore in the same period of previous...

Lupin's Etanercept biosimilar, developed by its Biotechnology Research Group in Pune will be the first product to be licensed for clinical ...

Used to treat gastroesophageal reflux disease.

Lupin had posted net profit of Rs 290.5 crore in July- September quarter of the previous fiscal, 2012-13.

Lupin has identified cancer drugs as the new focus area in the Japanese market where patents on products worth $ 2 billion are expected to ...

Drug firm Lupin is targeting to double sales in Japan to $500 million (over Rs 2,600 crore) in the next five years on the back of enhanced ...

The launch of Combivir generic is a positive development for Lupin. However, it will have to share the mkt with competitors viz. Teva & Aur...

Lupin Limited, the world's largest maker of drugs to fight tuberculosis, is considering selling its unit that markets drugs in India, said ...

Drug maker Lupin today said it is aiming to become one of the top five generic pharmaceutical companies in Japan in the next three years.

The company expects to launch 10 new products in Japan this year, considered the most difficult of three developed pharmaceutical markets -...

Drug firm Lupin on Monday said it has settled ongoing litigation over Lunesta tablets, used in treating insomnia, with Japan-based Dainippo...

Lupin has acquired 60% stake in Pharma Dynamics, a South African generic marketing firm.

The company plans to launch these products by July 2008. Lupin is the first Indian co to get approval from the Japanese drug authorities to...

In a bid to improve the profitability of its Japanese venture Kyowa Pharmaceutical Industry, Indian drug maker Lupin is planning to bring t...

Lupin’s acquisition in Japan gives it a foothold in a large pharmaceutical market with relatively low generic penetration. Japan is the wor...